About Avecia
Avecia is a company based in Milford (United States) founded in 1999 was acquired by Nitto in February 2011. Avecia offers products and services including Preclinical Manufacturing, Analytical Development, Process Development, and Drug Substance Manufacturing. Avecia operates in a competitive market with competitors including RiboBio, Liberate Bio, Shanghai Rui Platinum Biotechnology, Genedesign and Lerna Biopharma, among others.
- Headquarter Milford, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nitto Avecia
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avecia
Avecia offers a comprehensive portfolio of products and services, including Preclinical Manufacturing, Analytical Development, Process Development, and Drug Substance Manufacturing.
Provides custom solutions for preclinical oligonucleotide production.
Develops and validates methods for raw materials and final products.
Creates safe and cost-effective processes for oligonucleotide programs.
Offers complete manufacturing solutions with extensive experience.
People of Avecia
Unlock access to complete
Funding Insights of Avecia
Investors in Avecia
Avecia has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Nitto and USAGov.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entity focused on information and services
|
Locked | Locked | Locked | |
|
Diversified materials are manufactured and supplied for various industries.
|
Locked | Locked | Locked |
Investor details for Avecia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avecia
Investment portfolio details for Avecia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avecia
Detailed financials for Avecia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avecia Comparisons
Peer comparison for Avecia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avecia
Avecia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RiboBio, Liberate Bio, Shanghai Rui Platinum Biotechnology, Genedesign and Lerna Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of oligonucleotides
|
|
| Locked | Locked | Locked |
Contract manufacturing for tissue-specific nucleic acid therapeutics is provided.
|
|
| Locked | Locked | Locked |
Provider of drug research and development services
|
|
| Locked | Locked | Locked |
Nucleic acid development and manufacturing services are provided.
|
|
| Locked | Locked | Locked |
Develops nucleic acid therapeutics using chemistry and biological insights for effective treatments.
|
Detailed competitors of Avecia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avecia
Complete news archive for Avecia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avecia
Avecia was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Avecia is headquartered in Milford, United States.
Avecia was founded in 1999 in Milford, United States, and operates as a biotechnology firm serving as a contract development and manufacturing organization. Services are provided for oligonucleotide drug substances, including antisense RNA, siRNA, miRNA, aptamers, conjugates, and immunostimulatory types. Capabilities encompass backbone, base, sugar modifications, linkers, post-synthesis conjugates, and terminal phosphates. Complex small molecule synthesis is also handled. The company was acquired by Nitto Denko, a Japanese materials manufacturer.
Avecia's top competitors include Shandong Sanyuan Biotechnology, RiboBio and Liberate Bio.
Avecia offers Preclinical Manufacturing, Analytical Development, Process Development, and Drug Substance Manufacturing.